NASDAQ:VIGL Vigil Neuroscience (VIGL) Stock Price, News & Analysis → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free VIGL Stock Alerts $3.03 +0.29 (+10.58%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$2.67▼$3.0550-Day Range$2.58▼$3.4852-Week Range$2.50▼$11.11Volume71,507 shsAverage Volume53,839 shsMarket Capitalization$113.87 millionP/E RatioN/ADividend YieldN/APrice Target$17.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Vigil Neuroscience alerts: Email Address Vigil Neuroscience MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside474.3% Upside$17.40 Price TargetShort InterestBearish6.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.56) to ($2.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.97 out of 5 starsMedical Sector581st out of 904 stocksBiological Products, Except Diagnostic Industry93rd out of 153 stocks 3.3 Analyst's Opinion Consensus RatingVigil Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageVigil Neuroscience has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.18% of the float of Vigil Neuroscience has been sold short.Short Interest Ratio / Days to CoverVigil Neuroscience has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Vigil Neuroscience has recently decreased by 6.77%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVigil Neuroscience does not currently pay a dividend.Dividend GrowthVigil Neuroscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VIGL. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Vigil Neuroscience this week, compared to 1 article on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vigil Neuroscience insiders have not sold or bought any company stock.Percentage Held by Insiders33.45% of the stock of Vigil Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.64% of the stock of Vigil Neuroscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Vigil Neuroscience are expected to grow in the coming year, from ($2.56) to ($2.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vigil Neuroscience is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vigil Neuroscience is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVigil Neuroscience has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThe asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.That's why we have released our Free Precious Metals Investment Guide that explains all the details About Vigil Neuroscience Stock (NASDAQ:VIGL)Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.Read More VIGL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIGL Stock News HeadlinesMay 1, 2024 | americanbankingnews.comHead to Head Survey: BioAtla (NASDAQ:BCAB) vs. Vigil Neuroscience (NASDAQ:VIGL)April 18, 2024 | markets.businessinsider.comVigil Neuroscience Inc: A Strong Buy on Promising ALSP Drug Trial Outcomes and Biomarker BreakthroughsMay 5, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.April 17, 2024 | globenewswire.comVigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual MeetingMarch 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vigil Neuroscience on Promising Clinical Trials and Key Data ReadoutsMarch 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL) and Daxor (DXR)March 27, 2024 | markets.businessinsider.comBuy Rating Affirmed: Vigil Neuroscience’s Advancing TREM2 Programs and Strong Financial PositionMarch 26, 2024 | finanznachrichten.deVigil Neuroscience, Inc.: Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMay 5, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 26, 2024 | msn.comVigil Neuroscience GAAP EPS of -$0.57 in-lineMarch 26, 2024 | benzinga.comVigil Neuroscience: Q4 Earnings InsightsMarch 26, 2024 | investorplace.comVIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023March 26, 2024 | globenewswire.comVigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 24, 2024 | finance.yahoo.comIs Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?March 20, 2024 | finanznachrichten.deVigil Neuroscience, Inc.: Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical OfficerMarch 20, 2024 | seekingalpha.comVigil Neuroscience appoints Kaufmann as Chief Medical OfficerMarch 20, 2024 | markets.businessinsider.comVigil Neuroscience Appoints Petra Kaufmann As CMOMarch 20, 2024 | globenewswire.comVigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical OfficerMarch 16, 2024 | seekingalpha.comVIGL Vigil Neuroscience, Inc.March 13, 2024 | globenewswire.comVigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual MeetingMarch 12, 2024 | globenewswire.comVigil Neuroscience to Present at Stifel 2024 Virtual CNS DaysMarch 6, 2024 | globenewswire.comVigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024February 29, 2024 | globenewswire.comVigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024February 22, 2024 | benzinga.comVigil Neuroscience Stock (NASDAQ:VIGL) Insider TradesFebruary 7, 2024 | finance.yahoo.comVigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology ConferenceJanuary 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: AN2 Therapeutics, Inc. (ANTX) and Vigil Neuroscience Inc (VIGL)January 4, 2024 | finanznachrichten.deVigil Neuroscience, Inc.: Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 MilestonesSee More Headlines Receive VIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today5/05/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VIGL CUSIPN/A CIK1827087 Webvigilneuro.com Phone857-254-4445FaxN/AEmployees69Year FoundedN/APrice Target and Rating Average Stock Price Target$17.40 High Stock Price Target$24.00 Low Stock Price Target$4.00 Potential Upside/Downside+474.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.26% Return on Assets-49.50% Debt Debt-to-Equity RatioN/A Current Ratio10.45 Quick Ratio10.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book0.94Miscellaneous Outstanding Shares37,580,000Free Float25,012,000Market Cap$113.87 million OptionableNot Optionable Beta1.87 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Ivana Magovcevic-Liebisch J.D. (Age 57)Ph.D., President, CEO & Director Comp: $908.25kSharon MoraniSenior Director of Facilities & OperationsDr. David Gray Ph.D. (Age 49)Chief Scientific Officer Ms. Leah GibsonVice President of Investor Relations and Corporate CommunicationsMr. Christopher Verni J.D. (Age 49)General Counsel & Corporate Secretary April Effort M.B.A.M.S., VP & Head of Corporate DevelopmentMr. Evan A. Thackaberry DABT (Age 51)Ph.D., Senior VP & Head of Early Development Christian Mirescu Ph.D.VP & Head of NeuroimmunologyWeeteck Yeo Ph.D.Senior Vice President of Strategic OperationsAndreas Meier M.D.Senior Vice President of Clinical & Medical SciencesMore ExecutivesKey Competitorsbluebird bioNASDAQ:BLUEAlloVirNASDAQ:ALVRCurisNASDAQ:CRISaTyr PharmaNASDAQ:LIFESangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInsidersIvana Magovcevic-LiebischBought 4,000 shares on 11/20/2023Total: $15,000.00 ($3.75/share)View All Insider Transactions VIGL Stock Analysis - Frequently Asked Questions Should I buy or sell Vigil Neuroscience stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vigil Neuroscience in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VIGL shares. View VIGL analyst ratings or view top-rated stocks. What is Vigil Neuroscience's stock price target for 2024? 4 equities research analysts have issued 12-month target prices for Vigil Neuroscience's stock. Their VIGL share price targets range from $4.00 to $24.00. On average, they predict the company's share price to reach $17.40 in the next twelve months. This suggests a possible upside of 474.3% from the stock's current price. View analysts price targets for VIGL or view top-rated stocks among Wall Street analysts. How have VIGL shares performed in 2024? Vigil Neuroscience's stock was trading at $3.38 at the beginning of the year. Since then, VIGL stock has decreased by 10.4% and is now trading at $3.03. View the best growth stocks for 2024 here. When is Vigil Neuroscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our VIGL earnings forecast. How were Vigil Neuroscience's earnings last quarter? Vigil Neuroscience, Inc. (NASDAQ:VIGL) posted its quarterly earnings data on Tuesday, March, 26th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.56) by $0.01. When did Vigil Neuroscience IPO? Vigil Neuroscience (VIGL) raised $112 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 7,000,000 shares at a price of $15.00-$17.00 per share. How do I buy shares of Vigil Neuroscience? Shares of VIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIGL) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceDems have chosen Biden replacement?Paradigm PressUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vigil Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.